STOCK TITAN
  1. Home
  2. News
  3. FBIO

Fortress Biotech, Inc. - FBIO STOCK NEWS

Welcome to our dedicated page for Fortress Biotech news (Ticker: FBIO), a resource for investors and traders seeking the latest updates and insights on Fortress Biotech stock.

Fortress Biotech, Inc. (symbol: FBIO) is a pioneering biopharmaceutical company focused on acquiring, developing, and commercializing innovative pharmaceutical and biotechnology products. The company operates through a unique model of establishing subsidiary companies, collectively known as Fortress companies, to promote research, development, and commercialization efforts.

Fortress Biotech leverages its deep expertise in the biopharmaceutical industry and drug development to support its subsidiaries. The company offers funding, management services, and strategic guidance to bolster the success of its Fortress companies. This collaborative approach enables the subsidiaries to focus on breakthrough innovations while benefiting from Fortress Biotech's resources and infrastructure.

The company's diverse product portfolio includes several key products such as Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. These products span across therapeutic areas with a significant focus on dermatology, where Fortress derives the majority of its revenue. Beyond dermatology, the company and its subsidiaries are deeply engaged in biotechnology, pharmaceutical development, oncology, and therapeutics.

Fortress Biotech continuously seeks strategic partnerships, licensing opportunities, joint ventures, and public and private financing to accelerate and support its research and development programs. These collaborations aim to enhance the company's capacity to bring novel treatments to market and address unmet medical needs.

For the latest updates and events, including financial results discussions and corporate updates, Fortress Biotech frequently engages with its stakeholders through conference calls and press releases.

For more information or media inquiries, please contact:
Jaclyn Jaffe, Fortress Biotech, Inc.: (781) 652-4500, ir@fortressbiotech.com
Tony Plohoros, 6 Degrees: (908) 591-2839, tplohoros@6degreespr.com

News

Cyprium Therapeutics, a Fortress Biotech Subsidiary Company, Completes Asset Transfer of CUTX-101 Copper Histidinate Product Candidate for Treatment of Menkes Disease, to Sentynl Therapeutics, a Wholly-owned Subsidiary of Zydus Lifesciences Ltd.

Rhea-AI Summary
Cyprium Therapeutics, Inc. (Cyprium) received $4.5 million payment upon closing and remains eligible to receive royalties and up to $129 million in aggregate development and sales milestones from Sentynl Therapeutics, Inc. (Sentynl) for the transfer of its proprietary rights and FDA documents pertaining to CUTX-101, a Copper Histidinate product candidate for the treatment of Menkes disease. Cyprium will retain 100% ownership over any FDA priority review voucher that may be issued at NDA approval for CUTX-101. The transfer aims to reduce Cyprium's development-related spend and potentially expedite commercialization upon FDA approval, with the drug demonstrating a compelling safety and efficacy profile for the treatment of Menkes disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.87%
Tags
none
-
News

Journey Medical Corporation Announces Successful Completion of Pre-NDA Meeting with the FDA for DFD-29 to Treat Rosacea

Rhea-AI Summary
Journey Medical Corporation (Nasdaq: DERM) is on track to submit a New Drug Application to the FDA for DFD-29 around year-end of 2023. Positive topline data from Journey Medical’s two DFD-29 Phase 3 clinical trials for the treatment of rosacea were reported in July 2023, achieving all co-primary and secondary endpoints with no significant safety issues.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.1%
Tags
none
-
News

Fortress Biotech Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

Rhea-AI Summary
Fortress Biotech, Inc. (Nasdaq: FBIO) announced a 100% increase in total consolidated net revenue to $34.8 million in Q3 2023. The company is advancing late-stage clinical assets with potential NDA and BLA submissions to the FDA through 2024, including DFD-29 to treat rosacea. Recent corporate highlights include a $19 million upfront payment Journey Medical received for an exclusive license agreement with Maruho for commercialization of Qbrexza® in additional territories in Asia. Financial results show a decrease in consolidated cash, cash equivalents, and restricted cash to $74.7 million as of September 30, 2023, compared to $89.2 million as of June 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.55%
Tags
earnings
News

Fortress Biotech Announces Closing of $10.0 Million Public Offering

Rhea-AI Summary
Fortress Biotech, Inc. (Nasdaq: FBIO) announced the closing of a public offering, raising approximately $10.0 million in gross proceeds. The offering consisted of 5,885,000 units, each comprising one share of common stock and one warrant to purchase one share of common stock, at a public offering price of $1.70 per unit. The net proceeds will be utilized for general corporate purposes, including research and development, clinical trials, product manufacture, and working capital.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.55%
Tags
offering
-
News

Fortress Biotech Announces Pricing of $10.0 Million Public Offering

Rhea-AI Summary
Fortress Biotech, Inc. (Nasdaq: FBIO) announced the pricing of its public offering of 5,885,000 units at a price of $1.70 per unit, with gross proceeds expected to be approximately $10.0 million. Certain directors and officers participated in the offering, purchasing an aggregate amount of approximately $2.9 million of units. The net proceeds will be used for general corporate purposes, including research and development, clinical trials, and working capital.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-37.02%
Tags
offering
-
News

Fortress Biotech Announces Launch of Proposed Public Offering

Rhea-AI Summary
Fortress Biotech, Inc. (Nasdaq: FBIO) has announced a public offering of units, including common stock and warrants, with the proceeds intended for general corporate purposes such as research and development, clinical trials, and working capital. The offering is being made by means of a prospectus related to the effective registration statement on Form S-3 (File No. 333-258145) and is being handled by Roth Capital Partners.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-37.02%
Tags
offering
News

Journey Medical Corporation Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

Rhea-AI Summary
DERM: Journey Medical Corporation Announces 101% Increase in Net Revenues to $34.5 Million in Q3 2023, GAAP Net Income of $16.8 Million, and Exclusive License Agreement with Maruho Co., Ltd.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.62%
Tags
earnings
-
News

Journey Medical Corporation to Announce Third Quarter 2023 Financial Results on November 7, 2023

Rhea-AI Summary
Journey Medical Corporation will release its third quarter 2023 financial results on November 7, 2023. The company will host a conference call and audio webcast at 4:30 p.m. ET on the same day. Interested parties can join the call by dialing 1-866-777-2509 (domestic) or 1-412-317-5413 (international). A live audio webcast will also be available on Journey Medical's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.94%
Tags
earnings
-
News

Journey Medical Corporation Announces Data from Bioavailability Study of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) vs. Solodyn® (Minocycline Hydrochloride Extended-Release Tablets, 105 mg)

Rhea-AI Summary
Journey Medical announces data from a comparative bioavailability study of DFD-29 vs. Solodyn for the treatment of rosacea
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.33%
Tags
none
News

Fortress Biotech Announces Reverse Stock Split

Rhea-AI Summary
Fortress Biotech announces 1-for-15 reverse stock split to comply with Nasdaq minimum bid price requirement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.12%
Tags
none

FAQ

What is the current stock price of Fortress Biotech (FBIO)?

The current stock price of Fortress Biotech (FBIO) is $1.61 as of November 22, 2024.

What is the market cap of Fortress Biotech (FBIO)?

The market cap of Fortress Biotech (FBIO) is approximately 43.6M.

What does Fortress Biotech, Inc. do?

Fortress Biotech acquires, develops, and commercializes innovative pharmaceutical and biotechnology products.

What are Fortress companies?

Fortress companies are subsidiaries established by Fortress Biotech to focus on specialized research, development, and commercialization of biotech products.

What products does Fortress Biotech offer?

Fortress Biotech's portfolio includes Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm.

How does Fortress Biotech support its subsidiaries?

Fortress Biotech provides funding, management services, and strategic guidance to support the growth and success of its subsidiaries.

What is the primary revenue source for Fortress Biotech?

The majority of Fortress Biotech's revenue comes from its dermatology segment.

Does Fortress Biotech engage in partnerships?

Yes, Fortress Biotech frequently seeks licensing, partnerships, joint ventures, and public and private financings to support its development programs.

Which therapeutic areas does Fortress Biotech focus on?

Fortress Biotech and its subsidiaries focus on dermatology, biotechnology, pharmaceutical development, oncology, and therapeutics.

How can I get the latest news on Fortress Biotech?

You can stay updated by following Fortress Biotech's press releases and participating in their conference calls.

Who can I contact for more information about Fortress Biotech?

For more information, contact Jaclyn Jaffe at Fortress Biotech or Tony Plohoros at 6 Degrees.

Where can I find financial updates from Fortress Biotech?

Financial updates are provided through conference calls and press releases hosted by Fortress Biotech.

Stock FBIO logo
Fortress Biotech, Inc.

Nasdaq:FBIO

FBIO Rankings

#4929 Ranked by Market Cap
N/A Ranked by Dividends

FBIO Stock Data

43.62M
21.76M
21.21%
15.78%
9.51%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
BAY HARBOR ISLANDS